Researcher Profile

Researcher Profile

Monika Joshi, MD, MRCP

Monika Joshi, MD, MRCP

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Experimental Therapeutics
Disease Teams:
Genitourinary Cancer
muj14@psu.edu

Research Interests

  • Therapeutics
  • Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Renal Cell Carcinoma
  • Prostatic Neoplasms
  • Drug Therapy
  • Mutation
  • Immunotherapy
  • Urinary Bladder Neoplasms
  • Kidney Neoplasms
  • Smoking
  • Survival

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications

2019

Voss, MH, Bhatt, RS, Vogelzang, NJ, Fishman, M, Alter, RS, Rini, BI, Beck, JT, Joshi, M, Hauke, R, Atkins, MB, Burgess, E, Logan, TF, Shaffer, D, Parikh, R, Moazzam, N, Zhang, X, Glasser, C, Sherman, ML & Plimack, ER 2019, 'A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma', Cancer, vol. 125, no. 14, pp. 2400-2408. https://doi.org/10.1002/cncr.32061
Zhu, J, Hussain, M, Joshi, A, Truica, C, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, J & Joshi, M 2019, 'Effect of creative writing on mood in patients with cancer' BMJ Supportive and Palliative Care. https://doi.org/10.1136/bmjspcare-2018-001710
Zaleski, M, Gogoj, A, Walter, V, Raman, J, Kaag, MG, Merrill, S, Drabick, J, Joshi, M, Holder, S, Degraff, D & Warrick, J 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system' Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, J, Yin, M, Holder, S & Drabick, J 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04

2018

Yin, M, Grivas, P, Emamekhoo, H, Mendiratta, P, Ali, S, Hsu, JA, Vasekar, M, Drabick, J, Pal, S & Joshi, M 2018, 'ATM/RB1 mutations predict shorter overall survival in urothelial cancer', Oncotarget, vol. 9, no. 24, pp. 16891-16898. https://doi.org/10.18632/oncotarget.24738

2017

Venur, VA, Joshi, M, Nepple, KG & Zakharia, Y 2017, 'Spotlight on nivolumab in the treatment of renal cell carcinoma: Design, development, and place in therapy', Drug Design, Development and Therapy, vol. 11, pp. 1175-1182. https://doi.org/10.2147/DDDT.S110209

2016

Pizzola, C, Rizvi, SM & Joshi, M 2016, 'A new era of immunotherapy in prostate cancer' Current Molecular Pharmacology, vol. 9, no. 3, pp. 217-225. https://doi.org/10.2174/1874467208666150716120551
Al-Marrawi, MY, Mackley, H, Ali, S, Wagner Jr., H, Joshi, M, Holder, S, Kaag, MG, Mallon, C, Talamo, G & Drabick, J 2016, 'Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review', Clinical Genitourinary Cancer, vol. 14, no. 4, pp. e393-e399. https://doi.org/10.1016/j.clgc.2016.01.004
Zheng, H, Liu, X, Zhang, J, Rice, SJ, Wagman, M, Kong, Y, Zhu, L, Zhu, J, Joshi, M & Belani, C 2016, 'Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer', Oncotarget, vol. 7, no. 35, pp. 56233-56240. https://doi.org/10.18632/oncotarget.9316
Vasekar, M, Degraff, D & Joshi, M 2016, 'Immunotherapy in bladder cancer', Current Molecular Pharmacology, vol. 9, no. 3, pp. 242-251. https://doi.org/10.2174/1874467208666150716120945
Joshi, M, Millis, SZ, Arguello, D, Holder, S, Lamm, D, Reddy, S, Belani, C, Drabick, J & Vogelzang, NJ 2018, 'Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers', European Urology Focus, vol. 4, no. 1, pp. 94-97. https://doi.org/10.1016/j.euf.2016.06.011
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, H, Kaag, MG, Van De Putte, EEF, Horenblas, S & Drabick, J 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715. https://doi.org/10.1634/theoncologist.2015-0440
Joshi, M, Pal, SK & Drabick, J 2016, 'Novel approaches in cancer immunotherapy - A light at the end of the tunnel', Discovery medicine, vol. 21, no. 118.
Joshi, M, Vasekar, M, Grivas, P, Emamekhoo, H, Hsu, JA, Miller, VA, Stephens, PJ, Ali, SM, Ross, JS, Zhu, J, Warrick, J, Drabick, J, Holder, S, Kaag, MG, Li, M & Pal, SK 2016, 'Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma', Oncotarget, vol. 7, no. 32, pp. 52442-52449. https://doi.org/10.18632/oncotarget.9449
Yin, M, Wang, W, Rosenberg, J, Kaag, MG, Joshi, M, Holder, S, Tuanquin, L & Drabick, J 2016, 'Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review', Clinical Genitourinary Cancer, vol. 14, no. 2, pp. e203-e206. https://doi.org/10.1016/j.clgc.2015.11.008

2015

Joshi, M, Rizvi, SM & Belani, C 2015, 'Afatinib for the treatment of metastatic non-small cell lung cancer' Cancer Management and Research, vol. 7, pp. 75-82. https://doi.org/10.2147/CMAR.S51808
Holder, S, Drabick, J, Zhu, J & Joshi, M 2015, 'Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer' Cancer Biology and Therapy, vol. 16, no. 2, pp. 207-209. https://doi.org/10.1080/15384047.2014.1002687
Al-Marrawi, MY, Cream, L, Mallon, CA, Holder, S, Joshi, M, Harvey, H, Talamo, G & Drabick, J 2015, 'Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer' Journal of Clinical Oncology, vol. 33, no. 5, pp. 521-522. https://doi.org/10.1200/JCO.2014.59.7773
Rice, SJ, Liu, X, Miller, B, Joshi, M, Zhu, J, Caruso, C, Gilbert, C, Toth, J, Reed, MF, Rassaei, N, Das, A, Barochia, A, El-Bayoumy, K & Belani, C 2015, 'Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung' Proteomics, vol. 15, no. 18, pp. 3267-3277. https://doi.org/10.1002/pmic.201500029
Wang, W, Cheng, J, Mallon, C, Al-Marrawi, MY, Holder, S, Joshi, M, Kaag, MG, Talamo, G & Drabick, J 2015, 'Symptomatic secondary polycythemia induced by anti-VEGF therapy for the treatment of metastatic renal cell carcinoma: A case series and review' Clinical Genitourinary Cancer, vol. 13, no. 6, pp. e391-e395. https://doi.org/10.1016/j.clgc.2015.07.003
Lipkin, JS, Rizvi, SM, Gatalica, Z, Sarwani, N, Holder, S, Kaag, MG, Drabick, J & Joshi, M 2015, 'Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression' Cancer biology & therapy, vol. 16, no. 1, pp. 28-33. https://doi.org/10.4161/15384047.2014.972843
Joshi, M, Rice, SJ, Liu, X, Miller, B & Belani, C 2015, 'Trametinib with or without Vemurafenib in braf mutated non-small cell lung cancer' PLoS One, vol. 10, no. 2, 0118210. https://doi.org/10.1371/journal.pone.0118210

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)